HOXB13
Basic information
Region (hg38): 17:48724763-48728750
Links
Phenotypes
GenCC
Source:
- prostate cancer, hereditary, 9 (Strong), mode of inheritance: AD
- prostate cancer (Definitive), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HOXB13 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 254 | 258 | ||||
missense | 613 | 614 | ||||
nonsense | 30 | 30 | ||||
start loss | 4 | |||||
frameshift | 51 | 51 | ||||
inframe indel | 9 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 7 | 4 | 11 | |||
non coding | 19 | 27 | ||||
Total | 0 | 0 | 715 | 274 | 7 |
Variants in HOXB13
This is a list of pathogenic ClinVar variants found in the HOXB13 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-48726629-A-AG | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726634-G-GC | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726636-TC-T | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726637-C-T | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726638-C-G | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726638-C-CG | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726640-GA-G | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726640-G-GC | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726642-G-T | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726643-GA-G | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726644-A-C | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726644-A-G | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726646-CA-C | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726648-G-T | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726650-C-A | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726650-C-G | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726651-CA-C | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726652-A-C | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726653-G-A | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726653-G-T | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726654-C-G | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726655-A-C | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726658-C-G | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726658-C-T | Prostate cancer, hereditary, 1 | Uncertain significance (-) | ||
17-48726658-CA-C | Prostate cancer, hereditary, 1 | Uncertain significance (-) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HOXB13 | protein_coding | protein_coding | ENST00000290295 | 2 | 4416 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.69e-8 | 0.106 | 125719 | 0 | 29 | 125748 | 0.000115 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.00415 | 166 | 166 | 1.00 | 0.00000840 | 1803 |
Missense in Polyphen | 55 | 58.371 | 0.94224 | 699 | ||
Synonymous | -0.588 | 79 | 72.6 | 1.09 | 0.00000391 | 614 |
Loss of Function | -0.208 | 11 | 10.3 | 1.07 | 4.95e-7 | 113 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000239 | 0.000239 |
Ashkenazi Jewish | 0.0000993 | 0.0000992 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000150 | 0.000149 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000131 | 0.000131 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Binds preferentially to methylated DNA (PubMed:28473536). {ECO:0000269|PubMed:28473536}.;
- Disease
- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:22236224, ECO:0000269|PubMed:22714738, ECO:0000269|PubMed:23064873, ECO:0000269|PubMed:23292082, ECO:0000269|PubMed:25629170, ECO:0000269|PubMed:27424772}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;
- Pathway
- Regulation of Androgen receptor activity
(Consensus)
Recessive Scores
- pRec
- 0.147
Intolerance Scores
- loftool
- 0.364
- rvis_EVS
- -0.07
- rvis_percentile_EVS
- 48.12
Haploinsufficiency Scores
- pHI
- 0.238
- hipred
- N
- hipred_score
- 0.490
- ghis
- 0.408
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.990
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hoxb13
- Phenotype
- behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; reproductive system phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; cellular phenotype; endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan);
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;angiogenesis;epidermis development;response to wounding;response to testosterone;regulation of growth;prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis;epithelial cell maturation involved in prostate gland development
- Cellular component
- nucleoplasm;transcription factor complex
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;methyl-CpG binding;sequence-specific DNA binding